Mepolizumab


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : SC Severe refractory eosinophilic asthma 100 mg once every 4 weeks. Eosinophilic granulomatosis with polyangiitis 300 mg once every 4 weeks.
Dosage Details
Subcutaneous
Eosinophilic asthma
Adult: In patient with severe refractory case: 100 mg once every 4 weeks.
Child: 6-11 years 40 mg once every 4 weeks; ≥12 years Same as adult dose.

Subcutaneous
Eosinophilic granulomatosis with polyangiitis
Adult: 300 mg once every 4 weeks.
Reconstitution
Add 1.2 mL of sterile water for injection to a vial labelled as containing 100 mg to provide a final concentration of 100 mg/mL. Gently swirl to dissolve. Do not shake. If a mechanical reconstitution device (e.g. swirler) is utilised, swirl at 450 rpm not longer than 10 minutes or 1,000 rpm not longer than 5 minutes.
Special Precautions
Patient with parasitic/helminth infestation. Not indicated for the treatment of acute asthma, acute bronchospasm, status asthmaticus, and other eosinophilic conditions. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. angioedema, bronchospasm, hypotension, urticaria, rash), herpes zoster infection.
Gastrointestinal disorders: Upper abdominal pain.
General disorders and admin site conditions: Injection site reactions, fatigue, pyrexia.
Musculoskeletal and connective tissue disorders: Back pain, muscle spasm.
Nervous system disorders: Headache.
Renal and urinary disorders: UTI.
Respiratory, thoracic and mediastinal disorders: Lower respiratory tract infection, influenza, nasal congestion, pharyngitis.
Skin and subcutaneous tissue disorders: Eczema, pruritus.
MonitoringParameters
Monitor pulmonary function tests (e.g. FEV1, peak flow). Monitor marker for deteriorating asthma.
Action
Description: Mepolizumab is a humanised immunoglobulin G1 kappa (IgG1k) monoclonal antibody that selectively inhibits cytokine interleukin-5 (IL-5) resulting to reduced growth, differentiation, recruitment, activation, production and survival of eosinophils, thereby decreasing eosinophil-mediated inflammation.
Pharmacokinetics:
Absorption: Bioavailability: Approx 80%. Time to peak plasma concentration: 4-8 days.
Distribution: Volume of distribution: Approx 3.6 L.
Metabolism: Metabolised by proteolytic enzymes, widely distributed in the body and not restricted to hepatic tissues.
Excretion: Nonrenal. Terminal half-life: 16-22 days.
Storage
Powder for Inj: Store between 2-8°C. Do not freeze. Protect from light. Reconstituted solution: Store below 30°C.
ATC Classification
R03DX09 - mepolizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by MIMS based on Mepolizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in